# EDGAR Filing Document

**Accession Number:** 0001563880
**File Stem:** 0001209191-23-010184
**Filing Date:** 2023-2
**Character Count:** 9780
**Document Hash:** 2610b756632aa69fc17ff0e3baea2c35
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-010184.hdr.sgml**: 20230216

**ACCESSION NUMBER**: 0001209191-23-010184

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230216

**FILED AS OF DATE**: 20230216

**DATE AS OF CHANGE**: 20230216

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Simon Farrell
- **CENTRAL INDEX KEY:** 0001965585

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38886
- **FILM NUMBER:** 23639483

**MAIL ADDRESS:**
- **STREET 1:** C/O TREVI THERAPEUTICS, INC.
- **STREET 2:** 195 CHURCH STREET, FLOOR 14
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06510
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Trevi Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001563880
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 450834299
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 195 CHURCH STREET
- **STREET 2:** 14TH FLOOR
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06510
- **BUSINESS PHONE:** 203-304-2499

**MAIL ADDRESS:**
- **STREET 1:** 195 CHURCH STREET
- **STREET 2:** 14TH FLOOR
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06510

## Exhibit 24.1

```
<PRE>
LIMITED POWER OF ATTORNEY
FOR SECTION 16 REPORTING OBLIGATIONS

       Know all by these presents, that the undersigned hereby makes,
constitutes, and appoints each of
Jennifer L. Good, Lisa Delfini and Christopher Galletta signing singly and each
acting
individually, as the undersigned's true and lawful attorney-in-fact with full
power and authority as
hereinafter described to:
       (1)	execute for and on behalf of the undersigned, in the undersigned's
capacity as a director
or officer of Trevi Therapeutics, Inc. (the "Company"), Forms 3, 4, and 5
(including any amendments
thereto) in accordance with Section 16(a) of the Securities Exchange Act of
1934, as amended, and the
rules thereunder (the "Exchange Act");
       (2)	do and perform any and all acts for and on behalf of the undersigned
which may be
necessary or desirable to prepare, complete and execute any such Form 3, 4, or
5, prepare, complete and
execute any amendment or amendments thereto, and timely deliver and file such
form with the United
States Securities and Exchange Commission (the "SEC") and any stock exchange or
similar authority,
including without limitation the filing of a Form ID, Update Passphrase, or any
other application
materials to enable the undersigned to gain or maintain access to the Electronic
Data Gathering, Analysis
and Retrieval system of the SEC;
       (3)	seek or obtain, as the undersigned's representative and on the
undersigned's behalf,
information regarding transactions in the Company's securities from any third
party, including brokers,
employee benefit plan administrators and trustees, and the undersigned hereby
authorizes any such person
to release any such information to such attorney-in-fact and approves and
ratifies any such release of
information; and
       (4)	take any other action of any type whatsoever in connection with the
foregoing which, in
the opinion of such attorney-in-fact, may be of benefit to, in the best interest
of, or legally required by, the
undersigned, it being understood that the documents executed by such
attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and
conditions as such attorney-in-fact may approve in such attorney-in-fact's
discretion.
       The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and
perform any and every act and thing whatsoever requisite, necessary, or proper
to be done in the exercise
of any of the rights and powers herein granted,  as fully to all intents and
purposes as the undersigned
might or could do if personally present, with full power of substitution or
revocation, hereby ratifying and
confirming all that such attorney-in-fact, or such attorney-in-fact's substitute
or substitutes, shall lawfully
do or cause to be done by virtue of this power of attorney and the rights and
powers herein granted. The
undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request
of the undersigned, are not assuming nor relieving, nor is the Company assuming
nor relieving, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
The undersigned
acknowledges that neither the Company nor the foregoing attorneys-in-fact assume
(i) any liability for the
undersigned's responsibility to comply with the requirements of the Exchange
Act, (ii) any liability of the
undersigned for any failure to comply with such requirements, or (iii) any
obligation or liability of the
undersigned for profit disgorgement under Section l6(b) of the Exchange Act.
       This Power of Attorney shall remain in full force and effect until the
undersigned is no longer
required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of
and transactions in
securities issued by the Company, unless earlier revoked by the undersigned in a
signed writing delivered
to the foregoing attorneys-in-fact.

       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as
of February 10, 2023 at 11:54 am EST.

/s/ Farrell Simon
Name:  Farrell Simon

</PRE>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Simon Farrell<br><sub>(Last) (First) (Middle)</sub><br>C/O TREVI THERAPEUTICS, INC.<br>195 CHURCH STREET, 14TH FLOOR<br><sub>(Street)</sub><br>NEW HAVEN, CT 06510<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Trevi Therapeutics, Inc. [ TRVI ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-02-16 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Commercial Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 20650 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | <sup>(1)</sup> | 2030-09-21 | Common Stock | 75000 | $3.91 | D |  |
| Performance Stock Option (right to buy) | <sup>(2)</sup> | 2031-02-16 | Common Stock | 17500 | $3.21 | D |  |
| Stock Option (right to buy) | <sup>(3)</sup> | 2032-02-10 | Common Stock | 75000 | $0.511 | D |  |

---

### Footnotes:

(1) This option was granted on September 22, 2020. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on September 22, 2021 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through September 22, 2024.

(2) Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 17,500 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis.

(3) This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.

**Remarks:**
Exhibit Index: 24.1 Power of Attorney

**Signature:** /s/ Christopher Galletta, attorney-in-fact  
**Date:** 2023-02-16

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**